Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Lotronex Limited-Access Program Revisited By FDA In Patient Letter

Jan 28 2002

• By The Pink Sheet

Related Content

FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy

Jan 01 2001

Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations

Dec 04 2000

GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April

Jan 21 2002

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window